1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERSTANDING

1.1 Product identifier
Product Name: MVASI®
Common Name: bevacizumab-awwb
Chemical Name: Anti-VEGF monoclonal antibody
Synonyms: ABP 215

1.2 Relevant identified uses of the substance or mixture and uses advised against
Recommended Use: Pharmaceutical
Uses advised against: No information available

Manufacturer:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California  91320-1799
1-805-447-7233
1-805-447-1000

Emergency Telephone Number:
Chemtrec
NORTH AMERICA 1-800-424-9300,
INTERNATIONAL 1-703-527-3887

2. HAZARDS IDENTIFICATION

Emergency Overview
Pharmaceutical product intended for clinical and commercial manufacturing purposes only. Product contains bevacizumab-awwb, a biosimilar to bevacizumab, approved for treatment of cancer. Dosage contents may post a health hazard only if significant absorption occurs (e.g. inhalation after a major spill or leak). Avoid inhalation, skin contact, eye contact, and accidental ingestions. Does not meet GHS classification criteria and therefore is not classified.

2.1 - Classification of the drug substance or mixture (drug product in final form, not applicable)
REGULATION (EC) No 1272/2008
Not classified

2.2 Label elements
Not classified

2.3 Other Hazards  No information available
3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Ingredients: See below

Chemical Name: Anti-VEGF monoclonal antibody
CAS-No: 1438851-35-4

The drug product is supplied as a 100 mg or 400 mg, sterile, single-use, preservative-free solution in a vial to deliver 4 mL or 16 mL of bevacizumab-arwb for intravenous infusion. Each vial contains 25 mg/mL of bevacizumab-arwb in the following: α,α-trehalose dihydrate, sodium phosphate, polysorbate 20, pH 6.2.

4. FIRST AID MEASURES

4.1 Description of first-aid measures

Eye Contact: In the case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

Skin Contact: Wash off immediately with soap and plenty of water removing all contaminated clothes and shoes. Consult a physician if necessary.

Inhalation: Move to fresh air. If symptoms persist, call a physician.

Ingestion: If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

Notes to Physician: Treat symptomatically.

5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Flammable Properties: No information available.

Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

5.2 Special hazards arising from the substance or mixture

Hazardous Combustion Products: No information available.

5.3 Advice for firefighters

Protective Equipment and Precautions for Firefighters: As in any fire, wear self-contained breathing apparatus pressure-demand, NIOSH (approved) and full protective gear.
6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Spill Procedures: If material is released or spilled, cordon off spill area. Take proper precautions to minimize exposure by using appropriate personal protective equipment in cleaning up a spill. If in powder form, wet down spilled material to minimize airborne dispersion. Soak up material with absorbent e.g., paper towels, and wash spill area thoroughly with appropriate cleaning materials. Dispose of collected material in accordance with applicable waste disposal regulations. Avoid release to the environment.

7. HANDLING AND STORAGE

7.1 Precautions for Safe Handling

Handling and Storage: Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke in work areas. Use adequate ventilation to minimize exposure. Wash hands, face and other potentially exposed areas immediately after handling this material. Remove contaminated clothing prior to entering eating areas. Clean protective equipment thoroughly after each use. Store in a well ventilated area.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Occupational Exposure Limit: No exposure guidelines established by ACGIH, NIOSH or OSHA. Amgen recommends an occupational exposure limit (OEL) of 50 µg/m³ as an 8-hour time weighted average over a 40-hour work week. The OEL is designed as an acceptable airborne concentration of a substance for which it is believed that workers may be repeatedly exposed day after day without adverse health effects. Bevacizumab-awwb has been classified per Amgen's Hazard Classification System as an Occupational Exposure Band 3 compound (20 µg/m³ - 100 µg/m³).

Engineering Controls: When practicable, handle material in enclosed processes or in processes with effective local exhaust ventilation or within a chemical hood.

8.2 Exposure controls

Personal Protective Equipment

Eye/face Protection: Wear safety glasses with side shields, chemical splash goggles, or safety glasses with side shields and a full-face shield to prevent contact with eyes. The choice of protection should be based on the job activity and potential for exposure to the eyes and face.

Skin Protection: Use gloves or other appropriate personal protective equipment if skin contact with formulation is possible. Wear lab coat or other protective over garment if splashing is possible. The choice of protection should be based on the job activity and potential for skin contact.

Respiratory Protection: When possible, handle material in enclosed processes or containers. If it is properly handled with effective local exhaust ventilation or containment, respiratory protection may not be needed. For procedures involving larger quantities or dust/aerosol generating procedures such as weighing or a large transfer of liquids, an air-purifying respirator with NIOSH approval for dusts and mists may be needed. The choice of protection should be based on the job activity and the potential for exposure.

Other: Wash hands, face and other potentially exposed areas after handling material (especially before eating, drinking or smoking). Clean protective equipment thoroughly after each use.

8.3 Environmental exposure controls

Environmental Exposure Controls Avoid release to the environment.
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Clear to colorless</td>
</tr>
<tr>
<td>Physical State</td>
<td>Liquid</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>149 kDa</td>
</tr>
<tr>
<td>Odor</td>
<td>No information available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No information available</td>
</tr>
<tr>
<td>pH</td>
<td>6.2</td>
</tr>
<tr>
<td>Melting point (°C) VALUE</td>
<td>No information available</td>
</tr>
<tr>
<td>Flash Point</td>
<td>No information available</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>No information available</td>
</tr>
<tr>
<td>Lower explosive limit</td>
<td>No information available</td>
</tr>
<tr>
<td>Upper explosive limit</td>
<td>No information available</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>No information available</td>
</tr>
<tr>
<td>Vapor Density (air = 1)</td>
<td>No information available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No information available</td>
</tr>
<tr>
<td>Water Solubility</td>
<td>No information available</td>
</tr>
<tr>
<td>Partition Coefficient (log Kow)</td>
<td>No information available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No information available</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

10.1 Reactivity                   | No information available                   |
10.2 Chemical stability           | No information available                   |
10.3 Possibility of hazardous reactions | No information available |
10.4 Conditions to avoid          | No Information available                   |
10.5 Incompatible materials       | No information available                   |
10.6 Hazardous decomposition products | No information available |
10.7 Other information            | None                                       |

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute Toxicity: Based on available data, the GHS classification criteria are not met.
Skin corrosion/irritation: Based on available data, the GHS classification criteria are not met.
Serious eye damage/eye irritation: Based on available data, the GHS classification criteria are not met.
Respiratory or skin sensitization: Based on available data, the GHS classification criteria are not met.
Germ cell mutagenicity: Based on available data, the GHS classification criteria are not met.
Carcinogenicity: Based on available data, the GHS classification criteria are not met.
Reproductive toxicity: Based on available data, the GHS classification criteria are not met.
STOT - single exposure: Based on available data, the GHS classification criteria are not met.
STOT - repeated exposure: Based on available data, the GHS classification criteria are not met.
Aspiration Hazard: No information available.
12. ECOLOGICAL INFORMATION

12.1 Toxicity
Ecotoxicity effects: No information available

12.2 Persistence and degradability
Persistence/Degradability: No information available

12.3 Bioaccumulative potential
Bioaccumulation/ Accumulation: No information available

12.4 Mobility in soil
Mobility in Environmental Media: No information available

12.5 Results of PBT and vPvB assessment
Results of PBT and vPvB assessment: No information available

12.6 Other adverse effects
Other Adverse Effects: No information available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods
Waste Disposal Method: Dispose of waste according to prescribed federal, state, local and competent authority guidelines.

14. TRANSPORT INFORMATION

DOT: Not regulated by U.S. DOT, IATA, or IMDG.
15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

<table>
<thead>
<tr>
<th>Legend</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSCA</td>
<td>United States Toxic Substances Control Act Section 8(b) Inventory</td>
</tr>
<tr>
<td>EINECS/ELINCS</td>
<td>European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances</td>
</tr>
<tr>
<td>DSL/NDSL</td>
<td>Canadian Domestic Substances List/Non-Domestic Substances List</td>
</tr>
<tr>
<td>PICCS</td>
<td>Philippines Inventory of Chemicals and Chemical Substances</td>
</tr>
<tr>
<td>ENCS</td>
<td>Japan Existing and New Chemical Substances</td>
</tr>
<tr>
<td>CHINA</td>
<td>-</td>
</tr>
<tr>
<td>AICS</td>
<td>-</td>
</tr>
<tr>
<td>KECL</td>
<td>-</td>
</tr>
</tbody>
</table>

State Regulations

California Proposition 65: As a biosimilar, bevacizumab-awwb would be expected to have similar toxicological effects as bevacizumab. Bevacizumab, is listed as a developmental toxicant.

15.2 Chemical safety assessment

No CSA has been conducted.
Revision Number: 5

To the best of our knowledge, the information provided here is accurate as of the date of the Safety Data Sheet (SDS). The information is specific to the material that is the subject of this SDS and may not be valid when this material is used in combination with any other materials or in any process. Each user should review the information provided here in the context of the user’s intended manner of handling, using, processing, storing, transporting, and disposing of the material.

This information is provided without warranty or guarantee of any kind, whether express, implied or statutory, including without limitation warranty of fitness or merchantability for a particular purpose or noninfringement. No representation, warranty, or guarantee is made, and no liability is assumed, with respect to the material or the information contained in this SDS including without limitation its accuracy or completeness or the hazards of, or results obtained from, use of the material or the information contained here. Caution should be used in the handling, using, processing, storing, transporting, and disposing of the material.